ASCO GI 2024 | Noninvasive assessment of PD-L1 in esophagogastric cancer using 18F-BMS-986229 PET

Samuel Louis Cytryn, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents a pilot PET study (NCT04161781) using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer. The study aimed to address limitations of single-site biopsies for PD-L1 assessment. Among the ten patients who underwent PD-L1 PET imaging, safety and feasibility were confirmed, with no adverse events related to 18F-BMS-986229. PD-L1 PET imaging showed 88% concordance between radiographic and pathologic findings. Higher PD-L1 PET visualization scores correlated with increased PD-L1 CPS, indicating the potential of this non-invasive method as a companion diagnostic tool for identifying patients likely to benefit from PD-1 therapy. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.